Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97

Research output: Contribution to journalJournal articleCommissionedpeer-review

Standard

Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97. / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).

In: E F S A Journal, Vol. 13, No. 7, 4183, 2015.

Research output: Contribution to journalJournal articleCommissionedpeer-review

Harvard

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2015, 'Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97', E F S A Journal, vol. 13, no. 7, 4183. https://doi.org/10.2903/j.efsa.2015.4183

APA

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2015). Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97. E F S A Journal, 13(7), [4183]. https://doi.org/10.2903/j.efsa.2015.4183

Vancouver

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97. E F S A Journal. 2015;13(7). 4183. https://doi.org/10.2903/j.efsa.2015.4183

Author

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). / Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97. In: E F S A Journal. 2015 ; Vol. 13, No. 7.

Bibtex

@article{d22e8350c7aa4081a37e706037198692,
title = "Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97",
abstract = "Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on lacto-N-neotetraose as a novel food ingredient (NFI) submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. Lacto-N-neotetraose (LNnT) is a synthetic tetrasaccharide, which is intended to be used in infant and follow-on formulae, foods for special medical purposes for infants and young children and other foods for infants and young children, as well as in foods or food supplements for adults. The information provided on the potential mutagenicity of LNnT does not raise safety concerns as regards the genotoxicity of this NFI. Based on the observations from a sub-chronic 90-day toxicity study in rats, the Panel considers that the no observed adverse effect level is 2 500 mg/kg body weight per day. The applicant provided a double-blind, randomised, controlled clinical trial on the effects of LNnT consumed in combination with another oligosaccharide (2{\textquoteright}-O-fucosyllactose (2{\textquoteright}-FL)) in infants. The Panel concludes that LNnT is safe for infants (up to one year of age) when added to infant and follow-on formulae, in combination with 2{\textquoteright}-FL, at concentrations up to 0.6 g/L of LNnT and up to 1.2 g/L of 2{\textquoteright}-FL, at a ratio of 1:2 in the reconstituted formulae; is safe for young children (older than one year of age) when added to follow-on and young-child formulae, at concentrations up to 0.6 g/L of LNnT (alone or in combination with 2{\textquoteright}-FL, at concentrations up to 1.2 g/L, at a ratio of 1:2). The Panel also concludes that LNnT is safe when added to other foods at the uses and use levels proposed by the applicant.",
keywords = "Faculty of Science, Lacto-N-neotetraose, LNnT, Synthetic oligosaccharide, Novel food ingredient, Safety ",
author = "{EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)} and Inge Tetens and Sj{\"o}din, {Anders Mikael}",
note = "On request from the European Commission following an application by Glycom A/S. Question No.: EFSA-Q-2014-00862, adopted on 29 June 2015.",
year = "2015",
doi = "10.2903/j.efsa.2015.4183",
language = "English",
volume = "13",
journal = "E F S A Journal",
issn = "1831-4732",
publisher = "European Food Safety Authority (E F S A)",
number = "7",

}

RIS

TY - JOUR

T1 - Scientific Opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97

AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

AU - Tetens, Inge

AU - Sjödin, Anders Mikael

N1 - On request from the European Commission following an application by Glycom A/S. Question No.: EFSA-Q-2014-00862, adopted on 29 June 2015.

PY - 2015

Y1 - 2015

N2 - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on lacto-N-neotetraose as a novel food ingredient (NFI) submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. Lacto-N-neotetraose (LNnT) is a synthetic tetrasaccharide, which is intended to be used in infant and follow-on formulae, foods for special medical purposes for infants and young children and other foods for infants and young children, as well as in foods or food supplements for adults. The information provided on the potential mutagenicity of LNnT does not raise safety concerns as regards the genotoxicity of this NFI. Based on the observations from a sub-chronic 90-day toxicity study in rats, the Panel considers that the no observed adverse effect level is 2 500 mg/kg body weight per day. The applicant provided a double-blind, randomised, controlled clinical trial on the effects of LNnT consumed in combination with another oligosaccharide (2’-O-fucosyllactose (2’-FL)) in infants. The Panel concludes that LNnT is safe for infants (up to one year of age) when added to infant and follow-on formulae, in combination with 2’-FL, at concentrations up to 0.6 g/L of LNnT and up to 1.2 g/L of 2’-FL, at a ratio of 1:2 in the reconstituted formulae; is safe for young children (older than one year of age) when added to follow-on and young-child formulae, at concentrations up to 0.6 g/L of LNnT (alone or in combination with 2’-FL, at concentrations up to 1.2 g/L, at a ratio of 1:2). The Panel also concludes that LNnT is safe when added to other foods at the uses and use levels proposed by the applicant.

AB - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on lacto-N-neotetraose as a novel food ingredient (NFI) submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. Lacto-N-neotetraose (LNnT) is a synthetic tetrasaccharide, which is intended to be used in infant and follow-on formulae, foods for special medical purposes for infants and young children and other foods for infants and young children, as well as in foods or food supplements for adults. The information provided on the potential mutagenicity of LNnT does not raise safety concerns as regards the genotoxicity of this NFI. Based on the observations from a sub-chronic 90-day toxicity study in rats, the Panel considers that the no observed adverse effect level is 2 500 mg/kg body weight per day. The applicant provided a double-blind, randomised, controlled clinical trial on the effects of LNnT consumed in combination with another oligosaccharide (2’-O-fucosyllactose (2’-FL)) in infants. The Panel concludes that LNnT is safe for infants (up to one year of age) when added to infant and follow-on formulae, in combination with 2’-FL, at concentrations up to 0.6 g/L of LNnT and up to 1.2 g/L of 2’-FL, at a ratio of 1:2 in the reconstituted formulae; is safe for young children (older than one year of age) when added to follow-on and young-child formulae, at concentrations up to 0.6 g/L of LNnT (alone or in combination with 2’-FL, at concentrations up to 1.2 g/L, at a ratio of 1:2). The Panel also concludes that LNnT is safe when added to other foods at the uses and use levels proposed by the applicant.

KW - Faculty of Science

KW - Lacto-N-neotetraose

KW - LNnT

KW - Synthetic oligosaccharide

KW - Novel food ingredient

KW - Safety

U2 - 10.2903/j.efsa.2015.4183

DO - 10.2903/j.efsa.2015.4183

M3 - Journal article

VL - 13

JO - E F S A Journal

JF - E F S A Journal

SN - 1831-4732

IS - 7

M1 - 4183

ER -

ID: 179439136